Flexible, fully disposable GMP facility

History: Member of the global network since 2014.
Employees: more than 100
Technology:
• Mammalian Cell Culture
• Single Use Bioreactors
Capabilities:
• Upstream and downstream process optimization
• Clinical and commercial supply
• Fill & Finish
Key characteristics:
• Monoclonal antibodies and fusion proteins
• cGMP facilities are certified by the National Medical Products Administration of China (NMPA, formerly known as CFDA: China Food and Drug Administration)
• Our operations and quality systems meet the cGMP requirements of international regulatory authorities
• Providing first-class biopharmaceutical medicines to China and to the global market

We deliver progress – and it’s our pleasure.

Boehringer Ingelheim BioXcellence™ welcomes your inquiries, questions and feedback.

www.bioxcellence.com
bioxcellence@boehringer-ingelheim.com

Discover Boehringer Ingelheims’ global career opportunities:
www.careers.boehringer-ingelheim.com

February 2019
Flagship site for large scale and commercial manufacturing in cell culture

**History:** Boehringer Ingelheim’s first mammalian cell culture facility started in 1983 and became the largest in Europe.
**Employees:** more than 2,000
**Technology:**
- Mammalian Cell Culture
- Stainless Steel and Single-Use Bioreactors
**Capabilities:**
- Center of excellence in cell line and process development
- Clinical and commercial supply
- Fill & Finish
**Key characteristics:**
- Launch site for almost all of our customers commercial mammalian products
- Monoclonal antibodies, fusion proteins, antibody fragments, complex antibodies, enzymes and other recombinant proteins
- 60 different biopharmaceuticals and about 80 different processes for manufacturing pre-clinical and clinical material

Specialists for microbial fermentation

**History:** The microbial fermentation facility was built in 1983 and expanded in 2005; Groundbreaking for mammalian cell culture facility was in 2017.
**Employees:** more than 800
**Technology:**
- Microbial technologies
- Mammalian Cell Culture to be in place 2021
- Stainless Steel and Single-Use Bioreactors
**Capabilities:**
- Cell line and process development
- Clinical and commercial supply
- Fill & Finish
**Key characteristics:**
- Several independent fermentation facilities for *E.coli* and other bacteria as well as for yeast technologies
- Non-glycosylated recombinant proteins, antibody fragments, protein scaffolds, and plasmid DNA (pDNA)
- Fill & Finish of lyophilized and liquid drug product in vials for clinical supply

Mammalian Cell Culture Centre in the heart of Silicon Valley

**History:** Member of the global network since 2011, the site was further expanded in 2018.
**Employees:** more than 500
**Technology:**
- Mammalian Cell Culture
- Stainless Steel and Single-Use Bioreactors
- Fed batch, perfusion and fully continuous manufacturing
**Capabilities:**
- Process development
- Clinical and commercial supply
- Fill & Finish
**Key characteristics:**
- Monoclonal antibodies, fusion proteins, antibody fragments, complex antibodies, enzymes and other recombinant proteins
- Two identical, independent trains for Cell Culture and purification in 2 kL or 15 kL bioreactors
- Facility design based on extensive use of glass windows providing visibility into the manufacturing areas